- AbbVie's innovative oncology advancements spur stock momentum.
- Analysts predict a potential 22% upside for AbbVie shares.
- GuruFocus estimates a slight downside based on GF Value metrics.
AbbVie Inc. (NYSE: ABBV) has been making notable progress in its oncology division, showcasing promising developments such as ABBV-969 and ABBV-514 at the recent AACR Annual Meeting. These scientific breakthroughs have played a role in boosting the stock price by 4% over the past quarter. Analysts remain optimistic, envisioning further growth potential beyond the current trading price of approximately $206.27.
Wall Street Analysts' Forecast
Wall Street analysts have set a variety of one-year price targets for AbbVie Inc. (ABBV, Financial). Among 24 analysts, the average target price stands at $214.68, with high and low expectations ranging from $251.00 to $173.00, respectively. This average target suggests a potential upside of 22.21% from the current stock price of $175.67. For a more comprehensive analysis, visit the AbbVie Inc (ABBV) Forecast page.
In terms of broker consensus, 27 firms have contributed to AbbVie Inc's current average recommendation of 2.0, categorizing it as "Outperform." This rating uses a scale where 1 represents a Strong Buy and 5 signifies a Sell.
GF Value Analysis
The GF Value for AbbVie Inc (ABBV, Financial) is projected to be $167.99 in one year, indicating a potential downside of 4.37% from the present price of $175.67. The GF Value is GuruFocus's fair value estimate, calculated considering the stock's historical trading multiples, past business growth, and future performance projections. For further details, refer to the AbbVie Inc (ABBV) Summary page.
